Zymeworks (ZYME) Liabilities and Shareholders Equity (2021 - 2026)

Zymeworks has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $478.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 12.38% year-over-year to $478.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 13.8% YoY) and the FY2025 annual result came in at $346.5 million, down 25.17% from the prior year.
• Liabilities and Shareholders Equity improved to $478.2 million in Q1 2026 per ZYME's latest filing, from $346.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $648.7 million in Q4 2022 and troughed at $300.3 million in Q3 2022.
• A 5-year average of $491.0 million and a median of $487.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 85.29% in 2023, then dropped 25.17% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $648.7 million in 2022, then retreated by 10.46% to $580.9 million in 2023, then retreated by 20.28% to $463.1 million in 2024, then decreased by 25.17% to $346.5 million in 2025, then jumped by 38.0% to $478.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $478.2 million, $346.5 million, and $397.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.